Masaki Terabe

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint The immunoregulatory role of type I and type II NKT cells in cancer and other diseases
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 41 Room D702, 41 Medlars Drive, Bethesda, MD, 20892, USA
    Cancer Immunol Immunother 63:199-213. 2014
  2. pmc A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 202:1627-33. 2005
  3. pmc Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody
    Masaki Terabe
    Vaccine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:6560-9. 2009
  4. ncbi request reprint Role of IL-13 in regulation of anti-tumor immunity and tumor growth
    Masaki Terabe
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Cancer Immunol Immunother 53:79-85. 2004
  5. ncbi request reprint NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814, USA
    Trends Immunol 28:491-6. 2007
  6. ncbi request reprint Immunoregulatory T cells in tumor immunity
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 1578, USA
    Curr Opin Immunol 16:157-62. 2004
  7. ncbi request reprint CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta
    Masaki Terabe
    Vaccine Branch and Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH Bldg 10 Rm 6B12, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Cancer Res 66:3869-75. 2006
  8. pmc Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells
    Shun Takaku
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Cancer 126:1666-74. 2010
  9. doi request reprint Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1578, USA
    Cancer Res 68:1979-87. 2008
  10. ncbi request reprint Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10 Room 6B 12, 9000 Rockville Pk, Bethesda, MD 20892 1578, USA
    Cancer Immunol Immunother 57:907-12. 2008

Detail Information

Publications46

  1. doi request reprint The immunoregulatory role of type I and type II NKT cells in cancer and other diseases
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 41 Room D702, 41 Medlars Drive, Bethesda, MD, 20892, USA
    Cancer Immunol Immunother 63:199-213. 2014
    ..Here, we discuss the function of NKT cells in tumor immunity and their interaction with other regulatory cells, especially CD4(+)CD25(+)Foxp3(+) regulatory T cells. ..
  2. pmc A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 202:1627-33. 2005
    ....
  3. pmc Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody
    Masaki Terabe
    Vaccine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:6560-9. 2009
    ..Here, we investigated possible synergy between anti-TGF-beta (1D11) and a peptide vaccine on induction of antitumor immunity, and the mechanisms accounting for synergistic efficacy...
  4. ncbi request reprint Role of IL-13 in regulation of anti-tumor immunity and tumor growth
    Masaki Terabe
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Cancer Immunol Immunother 53:79-85. 2004
    ..Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves...
  5. ncbi request reprint NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20814, USA
    Trends Immunol 28:491-6. 2007
    ..Consideration of the cross-talk of NKT cells along with the well-defined suppression by regulatory T cells could provide new insights into cancer immunotherapy...
  6. ncbi request reprint Immunoregulatory T cells in tumor immunity
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 1578, USA
    Curr Opin Immunol 16:157-62. 2004
    ....
  7. ncbi request reprint CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta
    Masaki Terabe
    Vaccine Branch and Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH Bldg 10 Rm 6B12, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Cancer Res 66:3869-75. 2006
    ..These data suggest that a novel CD1d-restricted NKT cell-mediated mechanism for tumor immunosuppression is active in the K7M2 osteosarcoma model and that NKT cells can regulate immunosurveillance through more than one pathway...
  8. pmc Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells
    Shun Takaku
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Cancer 126:1666-74. 2010
    ....
  9. doi request reprint Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1578, USA
    Cancer Res 68:1979-87. 2008
    ..We conclude that a vaccine inducing antibodies to a functional oncogenic receptor could have tremendous therapeutic potential against cancers overexpressing such molecules...
  10. ncbi request reprint Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10 Room 6B 12, 9000 Rockville Pk, Bethesda, MD 20892 1578, USA
    Cancer Immunol Immunother 57:907-12. 2008
    ..However, it was unknown whether natural immunosurveillance inhibits growth of completely spontaneous autochthonous tumors, and whether it can be improved by inhibition of negative regulation...
  11. pmc IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells
    Masaki Terabe
    Vaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20893, USA
    J Immunol 180:7276-86. 2008
    ..1(+) T cell subset, CD8alphaalphaNK1.1(+) T cells, and that IL-15-transgenic mice may be a useful resource for studying the functional relevance of CD8(+)NK1.1(+) T cells...
  12. ncbi request reprint Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis
    Elena Ambrosino
    National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 179:5126-36. 2007
    ..Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer...
  13. ncbi request reprint Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 174:4228-36. 2005
    ..Such a vaccine may provide Ab-mediated protection against HER-2-expressing breast cancers in humans...
  14. ncbi request reprint Regulation of tumor immunity: the role of NKT cells
    Elena Ambrosino
    National Cancer Institute, Center for Cancer Research, Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, NIH, Building 10 Room 6B12, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    Expert Opin Biol Ther 8:725-34. 2008
    ..Recent studies suggest that NKT cells are a heterogeneous cell population with multiple subsets with distinct functions...
  15. doi request reprint A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 57:1679-83. 2008
    ..The balance along this axis may determine the outcome of tumor immunosurveillance as well as influence the efficacy of anti-cancer vaccines and immunotherapy...
  16. ncbi request reprint Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Cancer Res 66:4434-42. 2006
    ..Taken together, our results identify the human IL-13Ralpha2 chain as a novel tumor rejection antigen...
  17. ncbi request reprint Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
    Yoshio Sakai
    Cancer Gene Therapy Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1374, USA
    Cancer Res 64:8022-8. 2004
    ..Neu was markedly reduced in mice with anti-adenovirus antibody titers. DCs modified by recombinant adenoviruses expressing tumor-associated antigens may provide an effective antitumor vaccination strategy...
  18. pmc The role of NKT cells in tumor immunity
    Masaki Terabe
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    Adv Cancer Res 101:277-348. 2008
    ..Therefore, learning to manipulate the balance along the NKT regulatory axis may be critical to devising successful immunotherapies for cancer...
  19. pmc Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence
    Masaki Terabe
    Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 198:1741-52. 2003
    ....
  20. pmc β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy
    Jessica J O'Konek
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:4404-11. 2013
    ..The objective of this study was to determine whether β-ManCer induces anergy of iNKT cells...
  21. pmc Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice
    Takahiro Okazaki
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 6B 04 MSC 1578, NIH, Bethesda, MD 20892 1578, USA
    J Virol 80:10645-51. 2006
    ..Peptide vaccines based on such strategies may be worth testing for their ability to exert selective pressure against drug-resistant strains and thus delay or prevent the development of HIV with the M184V resistance mutation...
  22. pmc IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses
    Huifeng Yu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Leukoc Biol 90:205-14. 2011
    ..These results suggest that IL-15 may be useful in the development of therapeutic and preventive vaccines against cancers and viral infections in patients defective in CD4(+) Th cell...
  23. ncbi request reprint Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13
    Jong Myun Park
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 114:80-7. 2005
    ..Thus, even for a nonregressor tumor, immunosurveillance exists but is negatively regulated via CD4+ NKT cells possibly mediated by IL-13, and can be unmasked by removal of these negative regulatory components...
  24. pmc Progress on new vaccine strategies for the immunotherapy and prevention of cancer
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 113:1515-25. 2004
    ..This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer...
  25. pmc IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis
    SangKon Oh
    Vaccine Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Proc Natl Acad Sci U S A 105:5201-6. 2008
    ..These findings suggest new vaccine strategies against infections and cancers, especially in individuals with CD4-deficiency...
  26. ncbi request reprint The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection
    Antoun Toubaji
    Cancer Vaccine Section, Vaccine Branch, NCI, NIH, Bethesda, MD, United States
    Vaccine 25:5882-91. 2007
    ..This immune response was found to be long lasting and protective in tumor bearing mice...
  27. pmc Delicate balance among three types of T cells in concurrent regulation of tumor immunity
    Liat Izhak
    Vaccine Branch and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 73:1514-23. 2013
    ..As patients with cancer often have deficient type I NKT cell function, managing this delicate balance among 3 T-cell subsets may be critical for the success of immunotherapy for human cancer...
  28. pmc Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    Yongjun Sui
    Vaccine Branch, Biostatistics and Data Management Section, and Laboratory of Experimental Immunology, National Cancer Institute, and Laboratory of Host Defenses and Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:9843-8. 2010
    ..Thus, strategic use of molecular adjuvants can provide better mucosal protection through induction of both innate and adaptive immunity...
  29. ncbi request reprint NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis
    Jay A Berzofsky
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    J Immunol 180:3627-35. 2008
    ..Distinct NKT cell subsets play positive and negative regulatory roles and define a new immunoregulatory axis with broad implications for tumor immunity and other immunological and disease settings...
  30. pmc Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE
    Yi Hsiang Huang
    Institute of Clinical Medicine, Infection and Immunity Research Center, National Yang Ming University, Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan
    PLoS ONE 8:e64365. 2013
    ..A combination of POTE 553-1Y and POTE 323-3F epitopes might be an attractive vaccine strategy for HLA-A2 cancer patients to overcome tolerance induced by tumors and prevent escape...
  31. pmc A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models
    Hideyuki Nakashima
    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 187:4935-46. 2011
    ..These novel results provide a strong rationale for combining immunotoxins with cancer vaccines for the treatment of patients with advanced cancer...
  32. pmc Progress on new vaccine strategies against chronic viral infections
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, The Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Clin Invest 114:450-62. 2004
    ..We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines...
  33. ncbi request reprint Peptide vaccines against cancer
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Treat Res 123:115-36. 2005
  34. pmc A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:13020-5. 2002
    ..These results argue for a push-pull approach to maximize vaccine efficacy, especially for HIV and cancer...
  35. ncbi request reprint Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells
    SangKon Oh
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1578, USA
    Cancer Res 64:2610-8. 2004
    ..Our data suggest that HLA-A2-binding TARP epitopes and enhanced epitopes discovered in this study could be incorporated into a potential vaccine for both breast and prostate cancer...
  36. pmc Strategies to use immune modulators in therapeutic vaccines against cancer
    Jay A Berzofsky
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Semin Oncol 39:348-57. 2012
    ..Some of these strategies individually have now been translated into human clinical trials in cancer patients. Combinations of these in a push-pull approach are promising for the successful immunotherapy of cancer...
  37. pmc Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice
    Miranda S Oakley
    Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics and Evaluation Research, Food and Drug Administration, Bethesda, MD, USA
    PLoS ONE 4:e6793. 2009
    ..We find that OX40, a marker of both T cell activation and memory, is selectively upregulated in the brain during ECM and its distribution among CD4(+) and CD8(+) T cells accumulated in the brain vasculature is approximately equal...
  38. pmc KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells
    Dazhi Lai
    Laboratory of Cellular and Molecular Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 208:1093-103. 2011
    ..This work documents the impact of a small number of KLF13-dependent iNKT cells on the generation of memory-like CD8(+) T cells...
  39. pmc The contrasting roles of NKT cells in tumor immunity
    Jay A Berzofsky
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Curr Mol Med 9:667-72. 2009
    ..This axis may have broad implications beyond cancer, as NKT cells play a role in steering other adaptive immune responses. The balance along this axis could affect immunity to tumors and infectious diseases and responses to vaccines...
  40. pmc Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2
    Stefan Fichtner-Feigl
    Department of Surgery, University of Regensburg, Regensburg, Germany
    Cancer Res 68:3467-75. 2008
    ..Corroborative data were obtained using the 15-12RM fibrosarcoma model. These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity...
  41. ncbi request reprint Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent
    Suzanne Ostrand-Rosenberg
    Department of Biological Sciences, University of Maryland, 1000 Hilltop Circle, Baltimore, MD 21250, USA
    J Immunol 169:5796-804. 2002
    ....
  42. pmc An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments
    Jeong Seok Nam
    Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea
    Cancer Res 68:3835-43. 2008
    ..TGF-beta antibodies reverse this effect, and the absence of a major effect of TGF-beta antagonism on any one cell compartment may be critical for a good therapeutic window and the avoidance of autoimmune complications...
  43. pmc Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17
    Jeong Seok Nam
    Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Korea
    Cancer Res 68:3915-23. 2008
    ..Thus, in addition to suppressing immune surveillance, tumor-induced TGF-beta may actively subvert the CD8+ arm of the immune system into directly promoting tumor growth by an IL-17-dependent mechanism...
  44. ncbi request reprint Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors
    Koji Kawakami
    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville Pike, Rockville, Maryland, USA
    Clin Cancer Res 12:4678-86. 2006
    ....
  45. ncbi request reprint Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry
    Ligia A Pinto
    NCI Frederick SAIC Frederick, Frederick, Maryland, USA
    Cytometry B Clin Cytom 63:47-55. 2005
    ..The development of methods that would allow preservation of samples for flow cytometric analysis is important for the extension of this technology to field testing in settings where the equipment might be not readily accessible...
  46. ncbi request reprint Influence of H2 complex and non-H2 genes on progression of cutaneous lesions in mice infected with Leishmania amazonensis
    Masaki Terabe
    Department of Molecular Immunology, School of Agriculture and Life Sciences, University of Tokyo 113 6857, Japan
    Parasitol Int 53:217-21. 2004
    ..These results suggest that H2 complex controls the growth of L. amazonensis in cutaneous lesions, and that non-H2 genes inherited by BALB congenic mice have a more potent role than the H2 complex in lesion progression...